Suspended PHASE2 INTERVENTIONAL 1-arm NCT06214793

Taletrectinib in Previously Treated Metastatic CDH1-mutated Invasive Lobular Cancer (ILC)

A Phase II Study of Taletrectinib in Previously Treated Metastatic CDH1-mutated Invasive Lobular Cancer (ILC) of the Breast (TaCe)

Sponsor: AnHeart Therapeutics Inc.

Conditions Breast Cancer Metastatic Breast Cancer

Interventions Taletrectinib

Updated 7 times since 2024 Last updated: Apr 30, 2025 Started: Apr 30, 2026 Primary completion: Jan 1, 2030 Completion: Jan 1, 2030

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Suspended

Anheart acquired by Nuvation Bio; leadership not moving forward

Listed as NCT06214793, this PHASE2 trial focuses on Breast Cancer and Metastatic Breast Cancer and remains suspended. Sponsored by AnHeart Therapeutics Inc., it has been updated 7 times since 2026, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

7 versions recorded

Jun 2025 — Present [monthly]

Suspended PHASE2
Dec 2024 — Jun 2025 [monthly]

Suspended PHASE2
Sep 2024 — Dec 2024 [monthly]

Suspended PHASE2

Status: Not Yet Recruiting → Suspended
Jul 2024 — Sep 2024 [monthly]

Not Yet Recruiting PHASE2
May 2024 — Jul 2024 [monthly]

Not Yet Recruiting PHASE2

▶ Show 2 earlier versions

Mar 2024 — May 2024 [monthly]

Not Yet Recruiting PHASE2
Feb 2024 — Mar 2024 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

AnHeart Therapeutics Inc.
Megan Kruse, MD

Data source: Case Comprehensive Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Cleveland, United States
• Weston, United States